Dear Reader,

I've just completed a research report that I believe could make a small group of people tens, if not hundreds, of thousands of dollars richer.

It contains many months of research on a tiny company I've uncovered that looks to be on the verge of a major breakthrough in the treatment of a very common form of brain cancer.

I'm so convinced that the work this company's doing will revolutionize the way late-stage brain cancer is treated, that I'm willing to make you a very bold promise.

I'm going to promise you this same stock will double its current price and be trading at $10 (or more) by June 25, 2010…

If it isn't, I'll write you a check myself.

Why June 25^th?

That's the month this company will meet up with scientists, Wall Street money managers and other industry experts in Chicago and likely reveal what only I and a few others intimately familiar with this company's work knows, which is:

When compared to the current FDA-approved treatment, this company's new drug is nearly doubling the life expectancy of a test group of patients with the most common and aggressive form of brain cancer.

Make no mistake about it.

This is a major development when it comes to advanced cancer treatments.

After all, when we see the FDA approving drugs that offer just a few weeks of additional survival… doubling the current survival rate is a significant breakthrough.

What's even more encouraging to me as a small pharmaceutical research specialist is that the drug not only appears to work substantially better than anything else on the market… but there have yet to be any findings of significant adverse side effects from using it.

Why is safety a crucial issue when it comes to new drug development?

Because the safety data on a drug can make or break a drug as far as the FDA is concerned…

Scientists could come along and develop a drug that quadruples a cancer patient's life expectancy… but if studies show the drug could seriously harm people in other ways, the FDA will not approve it; the drug will never come to market; and investors could be left holding an empty bag.

That's why I'm so excited about the prospects for this little company's new cancer drug…

If its performance and safety record holds true… and this company's drug becomes the new standard in brain cancer treatment, we could be looking at a billion or more in new revenue over the coming years.

From $5… to $10… to Over $66

Once investors get a sniff of the potential "breakthrough nature" of this cancer-fighting drug between now and next June, I believe the stock price will soar: From the $5 range it's trading at now…to $10 (or more) when final Phase II data results are announced this coming June… to perhaps even over $66 a share once the drug hits the market.

In other words, this could be one of "those" stock stories…

Where a tiny little drug company breaks through with a drug so important and so financially successful, that it helps spawn an entire pipeline of successful drugs – making early-in investors filthy rich in the process.

But it all starts with a single successful drug…

And between my many months of dissecting reams of data out on the current trial… looking long and hard at the company, its financials and its management team… and talking to key players I know in the biotech sector as a result of my 14 years of research in the small-cap pharma sector – this looks to be one of the most important cancer drugs to come along in many years.

And to promise you that, if I'm wrong about this, I'll sit down and write anyone who requests it a check for $1,250 myself.

I'll give you all the details in a minute…

The last time I did this…

The last time I sent out a letter to folks "promising" a stock would double in price, it did… and then some.

Maybe you saw the note?

It started out like this:

The very next day, we received results regarding a highly successful Phase III trial that paved the way for possible FDA approval of this tiny company's medical device.

The stock soared to over $10 a share as word of this little company and its impressive invention got out.

Needless to say, I heard from a lot of ecstatic folks who'd bought the shares on my recommendation, back when the stock was very low.

Like Peter T. from California, who wrote to say:

48% in 20 days: "Best Gain I've had in 2 years!"

"I bought 500 shares at an average price of $5.79, and sold 250 of them yesterday (20 days later) at $8.55! The best gain I've had in two years! Thanks."

Or Paul T., who was just as happy:

"As I write, the 250 of the 500 I bought at $5.1899 are now showing an increase of just over 80%, and my Access portfolio is currently up just over 31%. Many thanks for the work you do."

Ruby B. is yet another thrilled Access subscriber who benefited from my "early-in" research. Recently she wrote:

"I have 3,000 shares and gains of $5,776. Thank you! Access is awesome, to say the least."

But I don't think anyone was as thrilled as Wallace M. who used this recommendation to add over $380,000 gains to his portfolio, based on a recent share price of $10:

Over $380,400 IN GAINS… so far!

"I am sitting on 60,000 shares at an average cost of $3.70. I believe (this stock) could be the haymaker I've been searching for and so far nothing but positive news is coming out about the company. I would like to express my sincere gratitude for your service Mr. Lichtenfeld. You have a dedicated follower for as long as you're in the business."

That's what can happen when you're one of the first to own a stock in what I like to call "the gathering stages" – when quietly, behind the scenes, companies are doing their important research, assembling a top-notch management team, developing their product pipeline and attracting a small group of high-profile investors…

They're setting the stage, in essence – preparing for their future role as a respected developer and provider of groundbreaking and life-saving drugs.

There's little debate as to how rich you can become investing early-in on these companies.

Just take a look at drug giants Celgene, Amgen and Biogen – once small-cap drug discoveries like the one I'm telling you about:

Celgene traded for pennies a share while in the "discovery  and gathering" phases.

Once the company had had its first drug success with Thalomid in 1998 – the stock popped, soaring as high as $77, turning a $10,000 early on investment into as much as $1.7 million.

Amgen traded well under $1 while it was in the earliest stages of its discovery work before its drug Epogen led off an impressive drug pipeline that propelled the stock as high as $80. A $10,000 "early days" investment in Amgen could have put over $2.6 million in your retirement account.

Biogen was a 35-cent stock while it was developing its drug pipeline. Once approvals and sales started rolling in for its MS drug, Avonex, the stock climbed as high as $75 – turning that same $10,000 into over $2.1 million.

In a minute I'll show you why I believe this little drug company could follow a similar path... and why I think this stock is virtually assured to double in price by early June.

I'll also explain how you could turn a $10,000 stake into as much as $132,000 from this one drug alone – and as much as $278,000 if the next promising drug to come through this company's pipeline makes it to market.

Plus I'll show you how to take advantage of my "money where my mouth is" guarantee, where I pay you $1,250 if this stock doesn't at least double in price between now and June 25 of the coming year.

Research Average Investors Never See

My name is Marc Lichtenfeld.

I've been making a very successful living for over 14 years researching under-the-radar companies working on important innovations – first as a Senior Analyst at a highly respected Wall Street research firm, and most recently as the founder and research director of my own firm, The Access Research Group.

The work we do here at Access is second to none.

I'm talking about the kind of situations that can produce explosive profits: small innovative companies leading the next wave in biotech, healthcare and technology.

Companies you're never likely to hear about, except through us…

Small companies in those all-important "gathering" stages – with virtually unlimited upside potential ahead of them…

Millionaire Makers

I choose to specialize in these companies because these are the companies that I've watched make so many Wall Street insiders millionaires many times over.

I know it can happen.

In the short time my Access service has been delivering Wall Street caliber research to the average wealth builder, we've seen our share of overnight gains, too…

Like the little medical devices company that better than doubled for us when news of Phase III trial results were announced and eager investors piled in.

But my subscribers probably didn't have to "rush in and buy" like so many investors did. They  already knew about the stock. All we had to do was sit back and watch the stock soar as investors drove the stock higher and higher in a matter of hours.

The best news is, I believe there are a lot more profits to come.

After all the research I've done on this company (many, many hours and thousands of dollars worth), I'm convinced this stock could move even higher from here.

We're still expecting another "bump" if FDA approval comes in the next couple of months… and yet another (albeit more gradual) move higher if profits from this company's ground breaking cancer device start rolling in.

Throw in the potential for a buyout or a takeover and you're looking at an even bigger potential windfall.

Says Barron's: "A Powerhouse in Medical Devices"

Even Barron's, though late to the party (as is most of the mainstream media when it comes to little innovative companies like the ones we cover), said this company's device "could revolutionize the way doctors screen patients for cancer, and transform (this) firm into a powerhouse in medical devices."

Like I told readers when I first uncovered it: This little-known $4.75 stock could have the potential to one day trade at $42 a share… and turn a 10,000 share holding into $420,000 cash.

But it's not the only company in the Access portfolio that's rewarded our members with substantial near-term gains… and the potential for far more profits to come.

There's the little biotech company we uncovered that's developing a swine flu virus for China, Asia and Europe.

Up 51% and Moving Higher

When I recommended it this past July, few experts even knew it was a potential swine flu play. It was only after discussions with top management that I learned the company was ramping up production of its approved hepatitis drug because it could potentially be used as an immune system booster in the event of a swine flu outbreak, just like it was successfully used in the 2003 SARS outbreak.

Within six weeks of my recommendation, word started to get out about this company's "H1n1 connection" and the stock soared over 51%.

A 206% Gain Already

I learned late last year of a little company favored to be awarded a $100 million government contract for a small pox therapeutic drug.

Since word got out, we're up 206% on the play – and as I write you today, the contract has yet to be awarded!

Up 124%, With More "Catalyst" to Come

Back in March, I told Access members this tiny little $4.35 drug company could be trading by $10 by the end of the year. Sure enough, the stock has taken off, trading at over $9.70 a share – 124% gain so far with more room to run even higher.

Permit me to mention as well…

• The 87% "official" gains so far on our medical device company…
  
  
• The 206% gains so far on the government favored small pox company…
  
  
• The 51% on the "swine flu" play…
  
  
• And the 124% gain on the tiny drug company…

… All came during a period of time that saw the biggest fall in the stock markets in decades.

That's because the kind of companies I research move on rumors, news and specific "catalysts" proven to drive stocks higher – and not in line with the general markets.

Let's face it, if a company has invested many years and millions of dollars in cash and resources in a drug, device, or innovation that proves to save thousands of lives, earn millions of dollars or transform an entire industry, the market will not ignore it.

Once investors see evidence of a company's success – whether it be excellent trial results, an FDA approval, a strategic partnership deal, or a multi-million dollar contract – the stock price is likely to go up whether the markets are struggling or not.

That's precisely what happened with the recommendations I've told you about: In each case, an important "catalyst" came along and drove several of these little stocks substantially higher.

And while so many investors were watching their investments plummet, Access members had the opportunity to watch many of theirs soar 51%, 87%, 124%... even 206%.

These are just the beginning…

But here's the thing…

I'm confident that the hard work we've done is about to pay even bigger dividends…

Why?

Because the various catalysts that are about to drive the companies we've been following are drawing very near. We expect most to happen within the next three months – "landmark events" that grab the market's attention and drive share prices of once little or unknown companies rocketing higher virtually over night.

Maybe it's an FDA approval… the consummation on an imminent deal… strong Phase II or Phase III test results… a major partnership deal… positive press… you name it.

Look no further than what happened to the shares of our little cancer device company when news of its Phase III success came out. The stock doubled, virtually over night.

That was catalyst #1…

It shot up again after Barron's wrote a glowing article about the company – catalyst #2.

From Small Cap to Industry Powerhouse

And then there are the longer-term gains that can come our way once the company's products gain acceptance in the marketplace and sales and profits begin to role in.

That's when a once speculative "small-cap" company turns into a full-fledged profit-generating powerhouse.

This is when knowing about a little company early on, buying shares at the most preferred prices, can turn a $5,000 or $10,000 investment into millions of dollars.

Which brings me full circle to the opportunity I'm writing to you about today…

The one where I'm willing to write any active member of my Access Research Group who requests it, a check for $1,250 if the company’s stock price doesn't double (or more) between now this coming June…

The Greatest Little Stock Nobody's Ever Heard of

Here's why I haven't been this excited about a new drug since BioMarin was developing its drug to treat Phenylketonuria – a disorder that can lead to mental impairments in infants – and went on to hand us gains ranging from 102% to 2,650% in just six months.

Only this story's much bigger.

Not only is the market much, much bigger – it's a drug that's taking on a much more common foe: brain cancer. And once a drug has been proven to work on one cancer, in many cases, it's just a matter of tinkering for it to work just as effectively on other cancers.

So far, this drug is doing what so many cancer drugs before it has failed to do. It's having an impact on survival.

Here's what a Duke University doctor wrote in a science journal about the group using this company's drug:

"Following vaccination, our group (the test group) has demonstrated potent, redirected cellular and humoral immunity against cancer cells expressing the mutant receptor without significant toxicity."

Translation?

The drug worked – without any apparent dangerous side effects!

That's why I'm confident this drug will be the breakthrough that a growing number of medical experts think it will.

And, I suspect, so does the drug giant who's ponied up a lot of cash to be in a partnership deal with this little company.

A $390 Million Pledge

In exchange for the right to market the drug upon FDA approval, the company is paying for all the development costs – plus it's agreed to pay up to $390 million in "milestone" payments as the drug moves through the approval process and into the marketplace.

Plus there's the double-digit royalties the company will receive based on sales when and if the drug is approved.

And what would sales of a drug like this one be?

No one can be sure, but the current standard in brain cancer treatment has over a billion dollars a year in sales. Given this drug could be proven even more effective when it comes to extending the lives of brain cancer patients, sales could be even greater.

Something else to consider.

If the company is successful with its brain cancer drug, it'll be in a much stronger position to land similar deals for earlier stage drugs, only with bigger upfront payments, bigger milestone payments and higher royalties since it'll have proven it can develop and launch a successful drug. 

Which brings me to another "wild card" I haven't even mentioned yet…

The company also has another promising drug in development that treats breast cancer. If successful, this drug could rival the sales of Genentech's Herceptin, which is the $1.5 billion per year drug that helped take that company's stock price from single digits to the $80 price it trades today.

I believe the company is holding off on a development deal with a major pharmaceutical company on this drug until it's had concrete success with the brain cancer drug early next year. That way, it'll be in a better position to negotiate a much more favorable deal…

As you can see, there's a lot going on here…

A lot of excitement and possibilities when it comes to a young, start-up company with any number of promising new drugs on its hands.

So what does it all mean to you if you were to buy shares of this little company today?

Four Stages of Profits

"Early-in" drug discovery opportunities like this one typically offer four stages of potential profit.

The stock can also move higher as "the buzz" starts to grow – things like prominent mentions at medical conferences and features in medical journals. There's typically another bump when the FDA-approval announcement hits the investment community.

Those early profit stages tend to produce big fast gains – 100%, 200% moves each time… typically in a matter of a few weeks.

I'm sure you've seen these, and perhaps wished you were part of the action:

• Cryolife, for instance, went from $6.75 to over $16 following its FDA clearance to market its heart-valve technology… a 137% gain.
  
  
• ATS Medical soared from $1.60 a share to over $3 when it received FDA approval for its mechanical heart valve… an 88% gain.
  
  
• Epix Pharmaceuticals went from 36 cents to $1.66 within two days when the FDA cleared its blood vessel imaging product late last year… a 361% gain.
  
  
• Or Human Genome Sciences, which recently soared from around $3.30 a share to $12.50 – a 279% gain – in a single trading session after the FDA approved its Lupus drug.
  

• EV3 Inc. better than doubled in the three weeks leading up to FDA approval for its balloon catheter products…

I like to call these "prospector profits" – big, generous rewards for those who had the courage (and the good fortune) to get in when risk was at its highest and nothing was certain.

I'm convinced anyone who follows the little cancer drug company I'm writing to you about will see similar "profit bumps" in the very near term… including the one that could come between now and the end of next June, as news of this company's work starts to filter out…

The second could come when the crucial Phase III results are delivered – and the third bump will happen should the FDA grant approval to the company to market the drug.

All of these, should they happen, will make for great "feel good" gains. After all, there's nothing more exciting than watching a stock you own double in a matter of days… or shoot up 50%, 70%.

But it's the fourth stage of profit that could have the biggest impact on your wealth.

What Would You Do With $132,000?

Right now, at around $5 a share, $10,000 would get you roughly 2,000 shares of this little company.

Let's forget for a moment about the potential doubles and other bumps from the near-term catalysts that can happen – Phase II and III trial results, FDA approval, articles published and so on.

Instead, let's look at what could happen to the stock price if the cancer drug is a success.

I've told you the deal it has: $390 million in "milestone" payments its drug giant partner must pay the company as the drug works its way through the approval process.

Plus a double-digit royalty on sales. The company's yet to disclose these terms, but let's say it's 20%.

With the potential to outsell the current brain cancer treatment by 20%, that would peg potential sales of the drug at $1.2 billion.

With a 20% royalty agreement in place, that would translate to $240 million in revenue from drug sales alone ($1.2 billion x 20%). Assign the industry average 9x sales multiple, and suddenly the market cap is $2.1 billion with a share price of $66.

Now your $10,000 is worth $132,000.

And that doesn't factor in the $390 million in milestones, which would be paid over several years.

But that's just based on one successful drug.

As I mentioned, the company also has a breast cancer drug with strong potential, as well – and a probable $1.5 billion market, based on the sales of the current treatment standard Herceptin.

Assuming the company gets a similar partnership for this drug as it has for its brain cancer drug (remember, it could be even better once it proves it can bring successful drugs to market), here's what the numbers look like:

$1.5 billion in sales x 20% = $300 million in revenues. Multiply that by the industry standard 9x sales multiple and you have an additional market cap of $2.7 billion… and another $73 in the share price.

How About $278,000?

But it all begins with the very first "catalyst" – the announcement of Phase II study results at a major Oncology event in early June.

That's why if you're looking for one stock that could have a dramatic impact on your financial future, you may want to consider a good look at this innovative little company.

In my opinion, this is a very real opportunity to get into a little drug company with the potential to be a future Amgen, Biogen, or Celgene – whose share price keeps growing and growing as it expands its line of cancer-fighting drugs year after year – with the potential to make early investors hundreds of thousands, even millions in profits.

That's why I'm writing you today.

It's to invite you to be a part of the many "first-in" opportunities we uncover by joining my Access Research Group.

When you do, I'll rush you the special "members only" research report I've just wrapped up on this exciting brain cancer drug company.

Why So Few Can Ever See This Report…

Like many of the companies we uncover here at Access, this is a small-capitalization situation.

Currently, only about 33 million shares trade on the open market.

Compare that to the roughly 1 billion shares a mature drug company like Amgen trades…

Or the 2 billion shares a company like Merck has outstanding…

Or the 6.7 billion shares a company like Pfizer has.

Of course the "smallness" of the company works very much to our advantage at this stage of the game – simply because of the enormous growth potential ahead of it.

But it does pose a problem from an investment standpoint.

Too many investors moving into this stock too quickly with too much cash could cause the stock to rise in an artificial manner – too high too fast.

So given the number of current Access subscribers who will get this report, I've determined that I must limit the number of reports I can issue.

That means as of now, I'll only be distributing 270 additional reports to new members, strictly on a first come, first serve basis.

Please understand I'm doing this for one reason and one reason only: To protect you and your fellow Access members who want to take advantage of this opportunity – and get in at a price that's fair and equitable.

That's why if you're at all interested in this outstanding opportunity – and want to have access to the full research reports on all the potentially profitable situations in the current Access portfolio, I urge you to sign up today.

That way you'll be assured to be one of the 270 new members to receive the brain cancer drug company research report.

But it's not the only outstanding money making opportunity you'll have access to the instant you join…

You'll also get to see all the research reports we've published – including details on companies poised on the verge of some of the very catalysts we predict will drive the stocks substantially higher in the days and weeks ahead…

Four More Plays That Could Deliver Money
Doubling Gains in the Coming Weeks

The company's products are approved and being used in Europe and Asia by doctors who are already finding new uses for it beyond what it’s approved for. Some are so excited by the product's life-saving potential that they're running their own clinical trials. The company is hoping to get FDA approval in the U.S. in 2010. When that happens, this $3 stock could double (or more) in a day…

Then there's the already profitable catheter company looking to sign an important, exclusive deal with a distributor for a new product that could be a gigantic seller – and could drive the company's shares 40% to 60% higher when the news breaks.

Or the tiny biotech company with the innovative and exciting "smart bomb" technology that attaches to an existing cancer drug and "targets" the disease directly.

Already in a partnership with a major pharmaceutical firm, Phase III data should be out early next year. If results are as strong as my research and contacts predict they'll be, this little $7.50 stock could soar 100% to 200% very quickly.

Or the little heart valve company that is quietly stealing market share from the big boys with their proprietary technology that marks the first substantial improvement in mechanical heart valve technology over the past 40 years.

My research suggests this young and innovative company could have its first profitable quarter soon – driving this $2.60 stock substantially higher on the news.

Best of all, the current economic uncertainty is likely to have little impact on any of these situations. These are well-capitalized companies with innovative new technology. And when the catalysts that we're expecting from the companies in our portfolio occur, we could still see explosive gains, no matter what's happening in the rest of the market.

That's why there's never been a better time to join Access.

First and foremost, you'll be among just a handful of people to learn about the new brain cancer drug company I'm so excited about – the one that could take you on a very fast and fun "profit ride" over the next couple of months… and longer term, pad your retirement account with hundreds of thousands of dollars.

There are all the great recommendations currently in our model portfolio – companies that have proven their worth with substantial gains already – but have many more to come, as the catalysts we've long said were coming loom just around the corner.

Of course there's all our future research as well. Like I told you before, a membership subscription to The Access Research Group is like gaining insight into a world very few investors ever see – companies on the verge of new and groundbreaking innovations… the kind of stuff most people don't hear about until long after the money's been made.

It's the kind of information portfolio that fund managers on Wall Street used to pay thousands of dollars for – just for a single report on a single opportunity... and millions of dollars for a full year, all for the kind of research you'll get as an Access member.

So what's it cost for a full year's subscription to Access?

The list price for Access is $6,000 per year. That's the price you'd pay if you were to visit our website and join up anytime we're not actively inviting new members in.

But this situation is a little different.

When I have a great stock I want to share, I like to make my research available to as many people as possible. So typically I'll agree to reduce the price for a very limited stretch of time.

Most recently, we reduced the price to $2,750 – and people jumped all over it. It was one of the most successful price offers since we launched Access.

But this time I want to make it even more attractive.

I want to give you as much incentive to join in now – so you can grab one of the 270 research reports I'm keeping aside on this little cancer company for new members – before they're all gone.

So for this offer only, the cost to join Access is just $1,250 – over half off our most recently offered price.

But in reality, your cost to join is zero.

Let me explain.

You've already heard the promise I'm willing to make any active Access member regarding the stock I'm writing to you about. I've made it very clear: If this stock doesn't double in price, from its roughly $5 price today, to over $10 a share by the end of this coming June, I'll write you a check.

So let's assume you buy 1,000 shares and the stock price does indeed double in the allotted time.

Your roughly $5,000 investment would be worth somewhere in the neighborhood of $10,000 – a nice $5,000 profit.

In this case, you've made back your $1,250 membership fee and much more from this one investment alone.

But let's say the stock doesn't double. Let's say it does nothing…or only goes up 50%... 60%... or even 90%...

Under the terms of this offer, I'd owe you a check…

And if you’re still with us come June 25th – and you haven’t refunded your membership for any reason – you may request and I’ll send you a check for $1,250, which is the full amount of your Access subscription price.

So you see, either way, you don't pay. Either the market pays for your subscription – or I do!

Please understand this is not a trial or limited offer.

Your $1,250 membership fee entitles you to see the exact research those who paid the full price get to see, month after month. You won't be charged any additional amounts or fees.

There's Just One "Catch"

It's limited to the number of people I feel comfortable sharing my latest recommendation with, simply because of the "small-cap" nature of this stock.

For now, that number is 270.

But I'll be watching the volume and price action on the stock carefully. If it looks like too much money is flowing into the stock too quickly, I reserve the right to pull this offer at any time.

That's why, if you're interested, I suggest you sign up right now.

When you do – and if you're among the first 270 to respond to this offer – you'll receive the special report I've just completed on the brain cancer drug company – and an opportunity to buy in now, before most investors have any clue about the work this great little drug researcher is doing.

You'll own it in plenty of time to watch a $10,000 investment potentially grow into hundreds of thousands, and maybe down the road even turn into the "million-dollar miracle" that will allow you retire in luxury.

And I'll promise you this: It won't be the only potentially life-changing stock we uncover…

What You Get With Your Access Membership

Here's what else you'll get as a member of our private research group:

• Six to eight recommendations per year on small-cap and micro-cap stocks, mainly in the healthcare and biotech fields. These companies are in the early stages of developing innovative and game-changing technologies, medicines and businesses. They'll have significant ownership by insiders and savvy, thought-leading investors with stellar long-term track records. We won't get involved unless we believe there is the potential for the stocks to at least triple in value over the next three years.
  
  
• An easy-to-read report with highlights and earnings estimates on the first "overview" page, followed by more detailed analysis, featuring our proprietary F.I.R.S.T. research methodology, beginning on page two. (Just like the reports I used to send billion-dollar portfolio managers at $10,000 to $30,000 a pop!)
  
  
• Weekly updates on the companies, competition, regulatory environment and market conditions.
  
  
• Breaking news updates. We'll let you know as soon as news breaks on one of our companies and what it could mean for the stock. You won't have to wait for the weekly update to receive our analysis. We'll alert you when it's time to add to a position or exit a play. You'll never be left wondering what to do.
  
  
• Private "Access members only" conference calls with the management of the companies we recommend, the Access team and other independent experts. (The call for company with the brain cancer drug is coming up fast – November 12th. Once you’re on board, we’ll send you all the details… along with instructions for submitting questions you’d like to ask me, the company’s management or the independent experts and specialists we invite to help ask the hard questions.)
  
  
• And, of course, full access to all the detailed research reports of the companies currently in our portfolio. (In fact, we're entering a three-month window where many of the catalysts we're expecting – signings, approvals and other deals that can drive the prices of stocks currently in our portfolio substantially higher still, virtually over night.)

So…

If you're interested in serious research – I'm talking small-cap and start-up companies that are in what I like to call "the gathering period" – where influential investors, insiders and sector specialists are accumulating substantial positions ahead of breakthrough news and/or product announcements…

If you want the kind of research typically reserved for portfolio managers and other Wall Street professionals, both in terms of the scope of information and the high upside profit-potential these undiscovered companies are known to deliver…

Then I urge you to activate your Access membership today in order to take advantage of the very special $1,250 price – over half off the discounted price we recently offered… and a better than 77% discount off the $6,000 published price.

And remember, if the little company I've been telling you about doesn't at least double in price between now and June 25, 2010 – and you’re an active, paid up member of my Access service, you can request from me, in writing by mail or e-mail, a check in the amount of $1,250.

So either the market pays for your Access subscription… or I do.

The Best Financial Decision You Can Make Today

Imagine knowing about the little drug company favored to sign a $100 million government contract for its small pox therapy – and having an opportunity to pocket 200% or more in gains… and we believe much more to come.

You'll be privy to information and research only a few company insiders could ever know (but can't share)… like when we learned about the little company ramping up production of its hepatitis drug because it could play an important role in the control of a swine flu outbreak – and the stock went up 50%.

This is the kind of approximate, "close to the bone" information that's the lifeblood of Wall Street insiders…

As a member of Access, you get the same powerful, wealth-transforming research for a fraction of the millions hedge funds and portfolio managers are willing to pay.

I wasn't kidding when I told you there has never been a better time to join us.

Forget for a moment about the discount I'm offering… or even the no risk "double or I write you a check" promise…

The real excitement begins when those great little companies in our model portfolio start taking off in earnest – popping 50%, 100% even 400% higher, often in a matter of days and weeks… when those much anticipated catalysts take place.

Of course, the most urgent reason to join us now is so you can be one of the 270 new members who'll see my newest recommendation…

…and watch it move higher as news of its successful Phase II data reaches Wall Street… and pop higher again when the company's breakthrough work is announced in Chicago in June of next year.

Take advantage of this deeply discounted membership price today by clicking here or by calling 888.570.9830 or 410.454.0498 and giving the VIP team Priority Code: NACCKA02.

Sincerely,

Marc Lichtenfeld
Founder & Director of Research
Access Research Group
October 2009

P.S. Just a reminder, I must hold firm to my initial 270 new member limit on the research reports concerning the tiny drug company with the potentially breakthrough brain cancer drug. At this point the company's so small that it can only handle a small number of investors getting in at any one time.

That said, this is a tremendous opportunity to be "first-in" with a innovative little drug company that could be the talk of the medical community when its brain cancer drug results are finally announced. That's why if you're interested in getting the report – plus a full year of Access for half the price (and the "double or else" guarantee I'm promising you) – I need to hear from you today!

And Lastly…

One more housekeeping issue. Obviously, I want my Access members to be thrilled with the research they’re receiving. That’s why I’m offering every new member this no-nonsense guarantee:

If after the first 60 days as an Access member you’re not delighted with the research you’re getting, simply tell us in writing (by my mail or e-mail) and I’ll cancel your membership and see to it that your full membership fee is returned to you in a prompt and courteous manner. So you see, there really is no risk. You can try Access for 60 days risk free – AND you get the “double or else” guarantee I’ve told you about.

ORDER NOW